Drugs / BCD-131
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02731469 | Jun 2016 → Mar 2017 | — | Biocad | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03519243 | Oct 2017 → Dec 2018 | anemia | Biocad | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07119372 | Mar 2025 → May 2026 overdue | anemia, end stage renal failure | Biocad | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD-131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07119372 ↗ |
| Known as | pegdarbepoetin beta | “BCD-131 (pegdarbepoetin beta), subcutaneous injection; regimen: once every 4 weeks; therapy duration: 84 weeks” NCT07119372 ↗ |
| Modality | Protein / enzyme biologic | “Biological: BCD-131” NCT03519243 ↗ |
| Route | Intravenous | “subcutaneous and intravenous injections of BCD-131” NCT02731469 ↗ |
| Route | Subcutaneous | “subcutaneous and intravenous injections of BCD-131” NCT02731469 ↗ |